SCHEMBL6333337

SCHEMBL6333337

COc1cc2c(cc1OC)C(=CC(C)Nc1ccccc1)C(=O)N2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 5/20 0.57
TLK2 Q86UE8 3/20 0.51
BRD4 O60885 2/20 0.42
CSNK1D P48730 3/20 0.41
CSNK1A1 P48729 2/20 0.41
CSNK1E P49674 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GMNN O75496 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP2C19 P33261 1/20 0.41
THPO P40225 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6779295 0.90 RET (0.51) RETTLK2BRD4L3MBTL1ALDH1A1
SCHEMBL6331394 0.89 RET (0.59) RETTLK2CCNB2CDK1CCNB1
SCHEMBL6338435 0.89 RET (0.48) RETTLK2BRD4CCNB2CDK1
SCHEMBL6329680 0.89 RET (0.49) RETTLK2BRD4CSNK1DCSNK1A1
SCHEMBL6330577 0.88 RET (0.47) RETTLK2BRD4CCNB2CDK1
SCHEMBL6330474 0.88 RET (0.47) RETTLK2BRD4MAPTMDM2
SCHEMBL6329191 0.88 RET (0.53) RETTLK2MAPTRAB9ANPC1
SCHEMBL6340156 0.88 RET (0.48) RETTLK2BRD4CSNK1DCSNK1A1
SCHEMBL6336804 0.87 RET (0.48) RETTLK2BRD4
SCHEMBL6338899 0.86 RET (0.46) RETTLK2BRD4FLT4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009898-A1 New substituted indolinones, their manufacture and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-01-13 US disclosed
US-6794395-B1 Substituted indolinones, their manufacture and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-09-21 US disclosed
EP-1212318-A1 SUBSTITUTED INDOLINONES AS TYROSINE KINASE INHIBITORS Boehringer Ingelheim Pharma KG (DE) 2002-06-12 EP disclosed
WO-2001016130-A1 SUBSTITUTED INDOLINONES AS TYROSINE KINASE INHIBITORS BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009898-A1 New substituted indolinones, their manufacture and their use as medicaments CCNE1, CDK1, CCNI RET 154/4885TLK2 1364/4885BRD4 439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.